Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a clinical trial of psilocybin-assisted psychotherapy in the treatment of patients suffering from Irritable Bowel Syndrome (IBS) who experience chronic abdominal pain and other debilitating gastrointestinal symptoms

Next Previous
Search
Trial Profile

Phase 2a clinical trial of psilocybin-assisted psychotherapy in the treatment of patients suffering from Irritable Bowel Syndrome (IBS) who experience chronic abdominal pain and other debilitating gastrointestinal symptoms

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Psilocybin (Primary)
  • Indications Abdominal pain
  • Focus Therapeutic Use

Most Recent Events

  • 08 Jan 2024 According to a Tryp Therapeutics media release, the company is preparing to initiate a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.
  • 08 Jan 2024 According to a Tryp Therapeutics media release, A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert with Psychotherapy Among Adult Patients with Irritable Bowel Syndrome is nearing commencement with patient dosing expected in the first half of 2024.
  • 13 Jul 2023 According to a Tryp Therapeutics media release, company has received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Tryp's Investigational New Drug ("IND") #163,994 is complete and the Company may proceed with its Phase 2a clinical trial at Massachusetts General Hospital (MGH)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top